10 results on '"Gardin, Claude"'
Search Results
2. Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
- Author
-
for the European ALMA + Investigators, Falantes, José, Itzykson, Raphael, Fenaux, Pierre, Pinto, Ricardo, Bargay, Joan, Burgstaller, Sonja, Martínez, María Pilar, Seegers, Valerie, Gardin, Claude, Cortesão, Emilia, Foncillas, María Ángeles, Montesinos, Pau, Sanz, Miguel Angel, Musto, Pellegrino, Pleyer, Lisa, Greil, Richard, Thépot, Sylvain, Almeida, António M., and Maurillo, Luca
- Subjects
HEALTH of older people ,MYELOID leukemia ,AZACITIDINE ,CANCER chemotherapy ,HEMATOLOGIC malignancies - Abstract
Azacitidine (AZA) prolonged overall survival (OS) in the AZA-AML-001 trial. However, few subjects were randomized to AZA or intensive chemotherapy (IC). The Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) developed a score for older AML patients receiving IC or non-intensive regimens, whereas the E-ALMA study validated a score for survival and response in elderly patients receiving AZA in daily practice. Both identified three groups with different risk estimates. This analysis evaluates the efficacy of frontline AZA in older AML patients (
N = 710) unfit for IC from different national registries (E-ALMA + series) stratified by the MRC/LRF risk score. Median OS of patients categorized as good, standard and poor-risk groups by the MRC/LRF score was 13.4 (95% CI, 10.8-16), 12.4 (95% CI, 9.9-14.8), and 8.1 months (95% CI, 7-9.1), respectively (p = .0001). In conclusion, this is the largest retrospective cohort of older AML patients treated with AZA. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
3. Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial.
- Author
-
Cannas, Giovanna, Pautas, Cécile, Raffoux, Emmanuel, Quesnel, Bruno, Botton, Stéphane de, Revel, Thierry de, Reman, Oumedaly, Gardin, Claude, Elhamri, Mohamed, Boissel, Nicolas, Fenaux, Pierre, Michallet, Mauricette, Castaigne, Sylvie, Dombret, Hervé, and Thomas, Xavier
- Subjects
ACUTE myeloid leukemia ,INFECTION ,GRAM-positive bacterial infections ,LEUKEMIA ,CANCER chemotherapy ,ASPERGILLOSIS - Abstract
Infections are a major complication in patients with acute myeloid leukemia undergoing intensive chemotherapy. They remain a major cause of therapy-associated morbidity and mortality, and represent a frequent cause of treatment withdrawal. An analysis of the medical charts of 459 younger adults included in the multicenter Acute Leukemia French Association (ALFA)-9802 trial showed that 1369 febrile episodes occurred among the 459 registered patients, including fever without identifiable source (23%) and clinically or microbiologically documented infections (77%). Bloodstream infections occurred in 314 episodes, including 129 documented episodes with Gram-positive and 96 with Gram-negative pathogens. Pulmonary infection was diagnosed in 144/1054 documented infectious episodes (14%). Invasive fungal infection was probable or proven in 116 patients. In all, 15 patients died of infection-associated complications, of whom seven died during early induction therapy, one during salvage therapy and seven during consolidation therapy. Better supportive care strategies may improve overall survival in patients undergoing chemotherapy for acute myeloid leukemia. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
4. Which AML Subsets Benefit From Leukemic Cell Priming During Chemotherapy? Long-Term Analysis of the ALFA-9802 GM-CSF Study.
- Author
-
Thomas, Xavier, Raffoux, Emmanuel, Renneville, Aline, Pautas, Cecile, de Botton, Stephane, Terre, Christine, Gardin, Claude, Hayette, Sandrine, Preudhomme, Claude, and Dombret, Herve
- Subjects
GRANULOCYTE-macrophage colony-stimulating factor ,ACUTE myeloid leukemia ,CELL cycle ,CYTOGENETICS ,GENETIC mutation ,SPONTANEOUS cancer regression ,PATIENTS ,THERAPEUTICS - Abstract
The article presents a study on leukemic cell priming with granulocyte-macrophage colony-stimulating factor (GM-CSF) which may modulate cell cycle kinetics and susceptible to phase-specific chemotherapeutic agents. In this study, cytogenetics, mutation detection and statistical analysis were used to 259 patients with acute myeloid leukemia (AML). The results show that priming of leukemia cells with GM-CSF may enhance complete remission (CR) rate and event-free survival (EFS).
- Published
- 2010
- Full Text
- View/download PDF
5. Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML).
- Author
-
Djamai, Hanane, Berrou, Jeannig, Dupont, Mélanie, Coudé, Marie-Magdelaine, Delord, Marc, Clappier, Emmanuelle, Marceau-Renaut, Alice, Kaci, Anna, Raffoux, Emmanuel, Itzykson, Raphaël, Berthier, Caroline, Wu, Hsin-Chieh, Hleihel, Rita, Bazarbachi, Ali, de Thé, Hugues, Baruchel, André, Gardin, Claude, Dombret, Hervé, and Braun, Thorsten
- Subjects
ACUTE myeloid leukemia ,ARSENIC trioxide ,HOMEOBOX genes ,CELL nuclei - Abstract
BET inhibitors (BETi) including OTX015 (MK-8628) and JQ1 demonstrated antileukemic activity including NPM1c AML cells. Nevertheless, the biological consequences of BETi in NPM1c AML were not fully investigated. Even if of better prognosis AML patients with NPM1c may relapse and treatment remains difficult. Differentiation-based therapy by all trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) demonstrated activity in NPM1c AML. We found that BETi, similar to ATO + ATRA, induced differentiation and apoptosis which was TP53 independent in the NPM1c cell line OCI-AML3 and primary cells. Furthermore, BETi induced proteasome-dependent degradation of NPM1c. BETi degraded NPM1c in the cytosol while BRD4 is degraded in the nucleus which suggests that restoration of the NPM1/BRD4 equilibrium in the nucleus of NPM1c cells is essential for the efficacy of BETi. While ATO + ATRA had significant biological activity in NPM1c IMS-M2 cell line, those cells were resistant to BETi. Gene profiling revealed that IMS-M2 cells probably resist to BETi by upregulation of LSC pathways independently of the downregulation of a core BET-responsive transcriptional program. ATO + ATRA downregulated a NPM1c specific HOX gene signature while anti-leukemic effects of BETi appear HOX gene independent. Our preclinical results encourage clinical testing of BETi in NPM1c AML patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. An Old AML Drug Revisited.
- Author
-
Dombret, Hervé and Gardin, Claude
- Subjects
- *
CLINICAL trials , *ACUTE myeloid leukemia , *ONCOLOGY , *OLD age - Abstract
The article highlights the long-term results of two large, randomized trials on managing acute myeloid leukemia (AML) conducted by investigators from the Eastern Cooperative Oncology Group (ECOG) in the U.S. and a collaborative group of European investigators from the Netherlands, Belgium, Germany and Switzerland. Among the factors that negatively influence the outcome of patients with AML are older age, poor performance status and high white-cell count. Both studies have concluded that the 90-milligram (mg) dose of daunorubicin, as compared with the standard 45-mg dose, appear to be similar. According to the authors, high-dose daunorubicin does not benefit the majority of older patients with AML.
- Published
- 2009
- Full Text
- View/download PDF
7. Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial
- Author
-
Thomas, Xavier, Raffoux, Emmanuel, Renneville, Aline, Pautas, Cécile, de Botton, Stéphane, de Revel, Thierry, Reman, Oumedaly, Terré, Christine, Gardin, Claude, Chelghoum, Youcef, Boissel, Nicolas, Quesnel, Bruno, Cordonnier, Catherine, Bourhis, Jean-Henri, Elhamri, Mohamed, Fenaux, Pierre, Preudhomme, Claude, Socié, Gérard, Michallet, Mauricette, and Castaigne, Sylvie
- Subjects
- *
ACUTE myeloid leukemia treatment , *HEALTH outcome assessment , *STEM cell transplantation , *CLINICAL trials , *MEDICAL statistics , *ADOLESCENT medicine , *CANCER relapse - Abstract
Abstract: Forty-seven percent of adults with acute myeloid leukemia (AML) who entered the ALFA-9802 trial and achieved a first complete remission (CR) experienced a first relapse. We examined the outcome of these 190 adult patients. Eighty-four patients (44%) achieved a second CR. The median overall survival (OS) after relapse was 8.9months with a 2-year OS at 25%. Factors predicting a better outcome after relapse were stem cell transplant (SCT) performed in second CR and a first CR duration >1year. Risk groups defined at the time of diagnosis and treatment received in first CR also influenced the outcome after relapse. The best results were obtained in patients with core binding factor (CBF)-AML, while patients initially defined as favorable intermediate risk showed a similar outcome after relapse than those initially entering the poor risk group. We conclude that most adult patients with recurring AML could not be rescued using current available therapies, although allogeneic SCT remains the best therapeutic option at this stage of the disease. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
8. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia
- Author
-
Abdelhamid, Emna, Preudhomme, Claude, Helevaut, Nathalie, Nibourel, Olivier, Gardin, Claude, Rousselot, Philippe, Castaigne, Sylvie, Gruson, Bérengère, Berthon, Céline, Soua, Zohra, and Renneville, Aline
- Subjects
- *
MYELOID leukemia , *BIOMARKERS , *POLYMERASE chain reaction , *GENETIC mutation , *GENE expression , *POLYMERIZATION - Abstract
Abstract: FLT3 internal tandem duplication (FLT3-ITD) is usually considered as a bad marker for minimal residual disease (MRD) follow-up in acute myeloid leukemia (AML). Our objective was to evaluate the suitability of FLT3-ITD as a target for MRD detection by real-time quantitative PCR, in comparison with two other molecular MRD markers, NPM1 mutation and WT1 overexpression, in 20 adult AML patients treated in Acute Leukemia French Association (ALFA) trials. Overall, these 3 MRD markers showed comparable kinetics in 17/20 (85%) cases. Furthermore, we found that FLT3-ITD MRD levels after induction chemotherapy are predictive of complete remission duration. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
9. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.
- Author
-
Thomas, Xavier, Elhamri, Mohamed, Raffoux, Emmanuel, Renneville, Aline, Pautas, Cécile, de Botton, Stéphane, de Revel, Thierry, Reman, Oumedaly, Terré, Christine, Gardin, Claude, Chelghoum, Youcef, Boissel, Nicolas, Quesnel, Bruno, Hicheri, Yosr, Bourhis, Jean-Henri, Fenaux, Pierre, Preudhomme, Claude, Michallet, Mauricette, Castaigne, Sylvie, and Dombret, Hervé
- Subjects
- *
DRUG dosage , *CYTARABINE , *ACUTE myeloid leukemia , *CANCER chemotherapy , *LEUKEMIA , *CLINICAL trials , *PATIENTS - Abstract
To assess the value of administering timed-sequential chemotherapy (TSC; 2 therapeutic sequences separated by a 4-day interval-free chemotherapy) or high-dose cytarabine (HDAraC) cycles in consolidation therapy for acute myeloid leukemia (AML), 459 patients 15 to 50 years of age were enrolled in the prospective randomized Acute Leukemia French Association-9802 trial. Complete remission was achieved in 89%. A total of 237 patients were then randomized to either TSC consolidation (120 patients) or HDAraC consolidation cycles (117 patients). Overall, there was no significant difference between the 2 consolidation arms (5-year event-free survival [EFS]: 41% for HDAraC vs 35% for TSC), or cumulative incidence of relapse, or treatment-related mortality. Cytogenetically normal AML NPM1+ or CEBPA+ and FLT3-ITD- had the same outcome as those with favorable cytogenetics. When considering favorable and unfavorable risk groups, the trend was in favor of HDAraC. However, the difference became significant when considering intermediate cytogenetics (5-year EFS: 49% vs 29%; P = .02), especially cytogenetically normal AML (5-year EFS: 48% vs 31%; P = .04), which was related to lower relapse rate and less toxicity. This study demonstrates that TSC did not produce any benefit when used as consolidation therapy in younger adults compared with HDAraC. This trial was registered at www.clinicaltrials.gov as #NCT00880243. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
10. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
- Author
-
Djamai, Hanane, Berrou, Jeannig, Dupont, Mélanie, Kaci, Anna, Ehlert, Jan Erik, Weber, Holger, Baruchel, André, Paublant, Fabrice, Prudent, Renaud, Gardin, Claude, Dombret, Hervé, and Braun, Thorsten
- Subjects
- *
ACUTE myeloid leukemia , *SMALL molecules , *DECITABINE , *AZACITIDINE , *CELLS , *CELL growth - Abstract
• LIM kinase 1 and 2 are expressed in FLT3-ITD mutated AML cell lines. • The LIMK1/2 inhibitor CEL_Amide has antiproliferative effects in those cells. • CEL_Amide synergizes with FLT3-ITD inhibitors in vitro and in vivo. • Dephosphorylation of cofilin constitutes a potential biomarker for LIMK1/2 action. Patients with FLT3-ITD mutated (FLT3-ITD+) Acute Myeloid Leukemia (AML), have frequently relapsed or refractory disease and FLT3-ITD+ inhibitors have limited efficacy. Rho kinases (ROCK) are constitutively activated by FLT3-ITD+ in AML via PI3 kinase and Rho GTPase. Upon activation by ROCK, LIM kinases (LIMK) inactivate cofilin by phosphorylation which affects cytoskeleton dynamics, cell growth and apoptosis. LIMK inhibition leads to cofilin activation via dephosphorylation and activated cofilin localizes to mitochondria inducing apoptosis. Thus, we investigated the therapeutic potential of the LIMK1/2 inhibitor CEL_Amide (LIMKi) in FLT3-ITD+ AML. Expression of LIMK1/2 in FLT3-ITD+ cell lines MOLM-13 and MV-4-11 cells could be detected by RT-qPCR and at the protein level. IC50 after LIMKi monotherapy was 440 nM in MOLM-13 cells and 420 nM in MV4-11 cells. Treatment with LIMKi decreased LIMK1 protein levels and repression of inactivating phosphorylation of cofilin in FLT3-ITD+ cells. Combination experiments with LIMKi and FLT3 inhibitors including midostaurin, crenolanib and gilteritinib were synergistic for treatment of MOLM-13 cells while combinations with quizartinib were additive. Combinations of LIMKi and the hypomethylating agent azacitidine or the ROCK inhibitor fasudil were additive. In NOD-SCID mice engrafted with MOLM13-LUC cells, the FLT3 inhibitor midostaurin and LIMKi delayed MOLM13-LUC engraftment as detected by in vivo bioluminescence imaging and the LIMKi and midostaurin combination prolonged significantly survival of leukemic mice. LIMK1/2 inhibition by the small molecule CEL_Amide seems to have promising activity in combination with FLT3 inhibitors in vitro as well as in vivo and may constitute a novel treatment strategy for FLT3-ITD+ AML. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.